Current Cancer Therapy Reviews
Title:Editorial: Prostate Cancer Immunotherapy
Volume: 8 Issue: 4
Author(s): Dr. Dev Karan and Peter Van Veldhuizen
Affiliation:
Export Options
About this article
Cite this article as:
Karan Dr. Dev and Van Veldhuizen Peter, Editorial: Prostate Cancer Immunotherapy, Current Cancer Therapy Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/1573394711208040237
DOI https://dx.doi.org/10.2174/1573394711208040237 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphotyrosine Phosphatases in Cancer Diagnostic and Treatment
Recent Patents on DNA & Gene Sequences Cancer Therapy Based on Smart Drug Delivery with Advanced Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Novel Inhibitory Activity for Serine Protease Inhibitor Kazal Type-3 (Spink3) on Human Recombinant Kallikreins
Protein & Peptide Letters The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Synthesis and Evaluation of <sup>198</sup>Au/PAMAM-MPEG-FA against Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Meridianins: Marine-Derived Potent Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry The Role of Insulin Resistance and Hyperinsulinemia in Cancer Causation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis
Current Vascular Pharmacology Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy
Current Drug Delivery Multifaceted Approach to Circadian Rhythm: Redox, Oxidative Stress, Melatonin, Antioxidants, Nitric Oxide, Hypoxia, Anesthetics, Cortisol and Cocaine
Current Chemical Biology microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets White Matter Neuroprotection in Preterm Infants
Current Pediatric Reviews